These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8786170)

  • 41. Dialysis therapy.
    Pastan S; Bailey J
    N Engl J Med; 1998 May; 338(20):1428-37. PubMed ID: 9580651
    [No Abstract]   [Full Text] [Related]  

  • 42. [The effect of the primary and repeated use of dialyzers with different membranes on the degree of dialysis-induced leukopenia].
    Strokov AG; Baeva LB; Levitskiĭ ER
    Med Tekh; 1990; (5):16-8. PubMed ID: 2273963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Are there long-term clinical consequences related to membrane biocompatibility?
    van Ypersele de Strihou C; De Meyer M
    Contrib Nephrol; 1989; 71():36-9. PubMed ID: 2680264
    [No Abstract]   [Full Text] [Related]  

  • 44. The 'first-use syndrome' revisited: a dialysis centre's perspective.
    Ing TS; Wong FK; Cheng YL; Potempa LD
    Nephrol Dial Transplant; 1995; 10 Suppl 10():39-44. PubMed ID: 8825431
    [No Abstract]   [Full Text] [Related]  

  • 45. Effect of membrane flux and dialyzer biocompatibility on survival in end-stage diabetic nephropathy.
    Götz AK; Böger CA; Popal M; Banas B; Krämer BK
    Nephron Clin Pract; 2008; 109(3):c154-60. PubMed ID: 18663328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Adhesion molecules in patients with chronic renal failure treated with haemodialysis].
    Musiał K; Zwolińska D
    Pol Merkur Lekarski; 2002 Sep; 13(75):177-81. PubMed ID: 12474564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leukopenia and complement activation induced by different dialysis membranes.
    Man NK; Tien NQ; Lesavre P; Funck-Brentano JL
    Contrib Nephrol; 1984; 37():142-8. PubMed ID: 6713867
    [No Abstract]   [Full Text] [Related]  

  • 48. Biocompatible dialysis membranes and oxidative stress in patients wih end-stage renal disease on maintenance haemodialysis.
    Abdel-Naeem NM; Kandell NF; El-Shamaa AA; Harba TM; Abdel-Hady AA
    J Egypt Soc Parasitol; 2005 Dec; 35(3 Suppl):1173-97. PubMed ID: 16363293
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Amyloidosis of the dialysis patient].
    van Ypersele de Strihou C
    Bull Mem Acad R Med Belg; 1988; 143(10-12):456-65; discussion 465-7. PubMed ID: 3077074
    [No Abstract]   [Full Text] [Related]  

  • 50. Dialysis membrane biocompatibility and mortality and morbidity in acute renal failure.
    Himmelfarb J; Hakim RM
    J Nephrol; 1997; 10(2):63-4. PubMed ID: 9238611
    [No Abstract]   [Full Text] [Related]  

  • 51. Biocompatibility and the clinical choice of dialysis membranes.
    Mujais SK; Ivanovich P; Bereza LA; Vidovich M
    Contrib Nephrol; 1995; 113():101-9. PubMed ID: 7712716
    [No Abstract]   [Full Text] [Related]  

  • 52. Importance of endotoxins in high-flux dialysis.
    Smollich BP; Falkenhagen D; Schneidewind J; Mitzner S; Klinkmann H
    Nephrol Dial Transplant; 1991; 6 Suppl 3():83-5. PubMed ID: 1775273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of dialysis membranes in infection.
    Vanholder R; Van Loo A; Dhondt AM; Ringoir S
    Nephrol Dial Transplant; 1996; 11 Suppl 2():101-3. PubMed ID: 8804006
    [No Abstract]   [Full Text] [Related]  

  • 54. Modified leukopenic response and complement activation during dialyzer reuse.
    Nakamura Y; Ozawa K; Akiba T; Matsui N; Yoshiyama N; Nakagawa S; Takeuchi J
    Proc Clin Dial Transplant Forum; 1980; 10():237-9. PubMed ID: 6810348
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy of choice of dialysis membrane.
    Koda Y; Suzuki M; Hirasawa Y
    Nephrol Dial Transplant; 2001; 16 Suppl 4():23-6. PubMed ID: 11402093
    [No Abstract]   [Full Text] [Related]  

  • 56. Delayed renal allograft function. Importance of the dialysis membrane.
    Pascual M; Tolkoff-Rubin N
    Transplantation; 1995 Oct; 60(7):769. PubMed ID: 7570993
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical sequelae of complement activation in hemodialysis.
    Hakim RM
    Clin Nephrol; 1986; 26 Suppl 1():S9-12. PubMed ID: 3829474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effect of hemodialysis with cuprophane and polysulfone membranes on counts of leukocytes, granulocytes, monocytes, lymphocytes and lymphocyte subsets].
    Moczulski D; Zukowska-Szczechowska E; Grzeszczak W; Religa Z; Cichoń R; Szydłowska I
    Pol Arch Med Wewn; 1994 Nov; 92(5):400-7. PubMed ID: 7885988
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Disorders of the respiratory function in patients with chronic renal failure treated by hemodialysis. II. Evaluation of pulmonary gas exchange and hemodialysis-related leukopenia].
    Wanic-Kossowska M
    Pol Arch Med Wewn; 1987 Oct; 78(4):223-9. PubMed ID: 3271301
    [No Abstract]   [Full Text] [Related]  

  • 60. Role of protein adsorption on haemodialysis-induced complement activation and neutrophil defects.
    Neveceral P; Markert M; Wauters JP
    Nephrol Dial Transplant; 1995; 10(3):372-6. PubMed ID: 7792033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.